Concepedia

Disease Progression Control

Disease Progression Control is a tertiary prevention strategy that specifically intervenes to slow, halt, or reverse the advancement of an established disease through targeted clinical or public health interventions.

87

Publications

8.8K

Citations

780

Authors

366

Institutions

Publications per year

2017–2026

33

Parents

Publications

87

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Robert Gottlieb, Carlos Vaca, Roger Paredes et al. · New England Journal of Medicine · 2021 · 1.3K citations · Full text

, , +13

COVID-19 rapid guideline: managing the long-term effects of COVID-19

Care Excellence · 2020 · 1.1K citations

, , +12

Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination

Dan H. Barouch, Sampa Santra, Jörn E. Schmitz et al. · Science · 2000 · 885 citations

, , +17

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 834 citations · Full text

, , +17

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Andrew Weickhardt, Benjamin Scheier, Joseph Burke et al. · Journal of Thoracic Oncology · 2012 · 677 citations · Full text

, , +15

1–5 of 87

Authors

780

  1. AN
    Ayako Nakajima

    Tokyo Women's Medical University, Japan

    2 publications · 22 citations

    2

    h-index

  2. TJ
    Thomas J. Kipps

    University of California San Diego, United States

    2 publications · 285 citations

    2

    h-index

  3. PV
    Peter Venner

    University of Alberta, Canada

    2 publications · 128 citations

    2

    h-index

  4. AT
    Atsuo Taniguchi

    Tokyo Women's Medical University, Japan

    2 publications · 22 citations

    2

    h-index

  5. EH
    Emily Hsu

    Dana-Farber Cancer Institute, United States

    2 publications · 285 citations

    2

    h-index

1–5 of 780

Institutions

366

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    5 h-index

    17 publications

    966 citations

  2. Harvard University

    Cambridge, United States

    5 h-index

    23 publications

    12.6K citations

  3. AbbVie (United States)

    North Chicago, United States

    4 h-index

    11 publications

    1.1K citations

  4. Vita-Salute San Raffaele University

    Milan, Italy

    4 h-index

    4 publications

    321 citations

  5. Massachusetts General Hospital

    Boston, United States

    4 h-index

    11 publications

    708 citations

  6. Dana-Farber Cancer Institute

    Boston, United States

    3 h-index

    8 publications

    1.6K citations

  7. McGill University

    Montreal, Canada

    3 h-index

    4 publications

    158 citations

  8. IRCCS Ospedale San Raffaele

    Milan, Italy

    3 h-index

    3 publications

    306 citations

1–8 of 366

Venues

  1. Cancer

    5 publications · 293 citations

    5

    h-index

  2. PubMed

    Repository · 5 publications · 84 citations

    5

    h-index

  3. AIDS

    3 publications · 46 citations

    3

    h-index

  4. Journal of Clinical Oncology

    3 publications · 1.5K citations

    3

    h-index

  5. Internal Medicine

    2 publications · 40 citations

    2

    h-index

1–5